- Home
- IMCR vs VERA Comparison
IMCR vs VERA Comparison
Compare IMCR & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- VERA
- Stock Information
- Founded
- IMCR 2008
- VERA 2016
- Country
- IMCR United Kingdom
- VERA United States
- Employees
- IMCR N/A
- VERA N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- VERA Biotechnology: Pharmaceutical Preparations
- Sector
- IMCR Health Care
- VERA Health Care
- Exchange
- IMCR Nasdaq
- VERA Nasdaq
- Market Cap
- IMCR 1.7B
- VERA 2.0B
- IPO Year
- IMCR 2021
- VERA 2021
- Fundamental
- Price
- IMCR $36.22
- VERA $23.20
- Analyst Decision
- IMCR Buy
- VERA Buy
- Analyst Count
- IMCR 10
- VERA 8
- Target Price
- IMCR $58.13
- VERA $64.63
- AVG Volume (30 Days)
- IMCR 286.3K
- VERA 1.2M
- Earning Date
- IMCR 08-07-2025
- VERA 08-07-2025
- Dividend Yield
- IMCR N/A
- VERA N/A
- EPS Growth
- IMCR N/A
- VERA N/A
- EPS
- IMCR N/A
- VERA N/A
- Revenue
- IMCR $333,581,000.00
- VERA N/A
- Revenue This Year
- IMCR $26.82
- VERA N/A
- Revenue Next Year
- IMCR $8.15
- VERA N/A
- P/E Ratio
- IMCR N/A
- VERA N/A
- Revenue Growth
- IMCR 25.75
- VERA N/A
- 52 Week Low
- IMCR $23.15
- VERA $18.53
- 52 Week High
- IMCR $40.88
- VERA $51.61
- Technical
- Relative Strength Index (RSI)
- IMCR 64.59
- VERA 52.49
- Support Level
- IMCR $32.20
- VERA $22.91
- Resistance Level
- IMCR $36.36
- VERA $24.58
- Average True Range (ATR)
- IMCR 1.18
- VERA 0.89
- MACD
- IMCR 0.33
- VERA 0.03
- Stochastic Oscillator
- IMCR 96.88
- VERA 59.90
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About VERA Vera Therapeutics Inc.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.